Bayer to Acquire Dihon Drugmaker
date：2014-12-23
browse：（1138）
Keyword：
Bayer announced to acquire privately held Dihon Pharmaceutical Group Co for RMB 3.6 billion. The deal, which could help Bayer challenge Johnson & Johnson to the No. 1 spot in the over-the-counter market, underscores its push into herbal medicine after it bought smaller German supplier Steigerwald last year.
Dihon is a maker of traditional Chinese medicines and its products include dandruff treatments, antifungal creams and medicine against gynaecological conditions such as endometriosis. Dihon's products are also exported to Nigeria, Vietnam, Burma and other countries. Dihon has about 2,400 employees and generated sales of 123 million euros (US$168 million) in 2013.
The latest article
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
